Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer

European Urology

Volumn 67, Issue 2, 2015, Pages 241-249

  Zargar, Homayoun ^a   Espiritu, Patrick N ^b   Fairey, Adrian S ^c,d   Mertens, Laura S ^e   Dinney, Colin P ^f   Mir, Maria C ^g   Krabbe, Laura Maria ^h   Cookson, Michael S ⁱ   Jacobsen, Niels Erik ^d   Gandhi, Nilay M ^j   Griffin, Joshua ^k   Montgomery, Jeffrey S ^l   Vasdev, Nikhil ^m   Yu, Evan Y ⁿ   Youssef, David ^a   Xylinas, Evanguelos ^o   Campain, Nicholas J ^p   Kassouf, Wassim ^q   Dall'Era, Marc A ^r   Seah, Jo An ^s   Ercole, Cesar E ^g   Horenblas, Simon ^e   Sridhar, Srikala S ^s   McGrath, John S ^p   Aning, Jonathan ^m,p   Shariat, Shahrokh F ^o,t   Wright, Jonathan L ⁿ   Thorpe, Andrew C ^m   Morgan, Todd M ^l   Holzbeierlein, Jeff M ^k   Bivalacqua, Trinity J ^j   North, Scott ^u   Barocas, Daniel A ^v   Lotan, Yair ^h   Garcia, Jorge A ^g   Stephenson, Andrew J ^g   Shah, Jay B ^f   Van Rhijn, Bas W ^e   Daneshmand, Siamak ^c   Spiess, Philippe E ^b   Black, Peter C ^a   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^m FREEMAN HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^p ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^q MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s PRINCESS MARGARET HOSPITAL   (Canada)

^t MEDICAL UNIVERSITY OF VIENNA   (Austria)

^u CROSS CANCER INSTITUTE   (Canada)

^v VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Complete pathologic response; Cystectomy; GC; MVAC; Neoadjuvant chemotherapy; Partial pathologic response; Urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINBLASTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NORTH AMERICA; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DOXORUBICIN; EUROPE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NORTH AMERICA; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84920658106     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.09.007     Document Type: Article

References (37)

1. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009 1018
2. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
3. Advanced Bladder Cancer Meta-Analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-Analysis Lancet 361 2003 1927 1934
4. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-Analysis of individual patient data Eur Urol 48 2005 202 205 discussion 205-6
5. G. Griffiths, R. Hall, R. Sylvester, D. Raghavan, and M.K. Parmar International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
6. G. Gandaglia, I. Popa, and F. Abdollah The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study Eur Urol 66 2014 561 568
7. D.C. Johnson, M.E. Nielsen, and J. Matthews Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity BJU Int 114 2014 221 228
8. H.B. Zaid, S.G. Patel, and C.J. Stimson Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database Urology 83 2014 75 80
9. P.J. Gray, S.A. Fedewa, and W.U. Shipley Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base Eur Urol 63 2013 823 829
10. M.S. Liew, A. Azad, and A. Tafreshi USANZ: time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer BJU Int 112 Suppl 2 2013 74 82
11. Z.D. Reardon, S.G. Patel, and H.B. Zaid Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides Eur Urol 67 2015 165 170
12. H. von der Maase, L. Sengelov, and J.T. Roberts Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602 4608
13. M.P. Porter, M.C. Kerrigan, B.M. Donato, and S.D. Ramsey Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252 258
14. A.S. Fairey, S. Daneshmand, and D. Quinn Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California Urol Oncol 31 2013 1737 1743
15. A. Dash, J.A. Pettus IV, and H.W. Herr A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience Cancer 113 2008 2471 2477
16. S.K. Pal, N.H. Ruel, T.G. Wilson, and B.E. Yuh Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer Clin Genitourin Cancer 10 2012 246 250
17. O. Yeshchina, G.M. Badalato, and M.S. Wosnitzer Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder Urology 79 2012 384 390
18. G. Sonpavde, B.H. Goldman, and V.O. Speights Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy Cancer 115 2009 4104 4109
19. F. Petrelli, A. Coinu, M. Cabiddu, M. Ghilardi, I. Vavassori, and S. Barni Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-Analysis Eur Urol 65 2014 350 357
20. R. Rosenblatt, A. Sherif, and E. Rintala Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229 1238
21. H. Kitamura, T. Tsukamoto, and T. Shibata Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group study JCOG0209 Ann Oncol 25 2014 1192 1198
22. V. Scattoni, A. Bolognesi, and C. Cozzarini Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results Tumori 82 1996 463 469
23. H.W. Herr, and H.I. Scher Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer J Clin Oncol 12 1994 975 980
24. G. Kaneko, E. Kikuchi, and K. Matsumoto Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer Jpn J Cin Oncol 41 2011 908 914
25. R.P. Meijer, J.A. Nieuwenhuijzen, and W. Meinhardt Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience Eur J Surg Oncol 39 2013 365 371
26. C.J. Weight, J.A. Garcia, and D.E. Hansel Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792 799
27. B.E. Yuh, N. Ruel, T.G. Wilson, N. Vogelzang, and S.K. Pal Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer J Urol 189 2013 1682 1686
28. D. Herchenhorn, R. Dienstmann, and F.A. Peixoto Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma Int Braz J Urol 33 2007 630 638 discussion 638
29. S. North, F. El-Gehani, and C. Santos Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy J Urol 191 2014 35 39
30. J.A. Witjes, E. Compérat, and N.C. Cowan EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines Eur Urol 65 2014 778 792
31. J. Bellmunt, A. Ribas, and N. Eres Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma Cancer 80 1997 1966 1972
32. D.C. Smith, N.J. Mackler, and R.L. Dunn Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder J Urol 180 2008 2384 2388 discussion 2388
33. R.W. deVere White, P.N. Lara Jr., and B. Goldman A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219) J Urol 181 2009 2476 2480 discussion 2480-1
34. P.D. Grivas, M. Hussain, and K. Hafez A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder Urology 82 2013 111 117
35. K. Iwasaki, W. Obara, Y. Kato, R. Takata, S. Tanji, and T. Fujioka Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer Jpn J Clin Oncol 43 2013 193 199
36. G. Niegisch, A. Lorch, M.J. Droller, H.J. Lavery, K.D. Stensland, and P. Albers Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol 64 2013 355 357
37. L.S. Mertens, R.P. Meijer, and J.M. Kerst Carboplatin based induction chemotherapy for nonorgan confined bladder cancer - a reasonable alternative for cisplatin unfit patients? J Urol 188 2012 1108 1113